Prebiotic Effects on Gut Microbiota, Gut Comfort and Immune Function

Last updated: February 4, 2025
Sponsor: Kyowa Hakko Bio Co., Ltd.
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Ulcers

Gastrointestinal Diseases And Disorders

Treatment

Placebo

HMO 1

HMO 2

Clinical Study ID

NCT06094153
2023-005
  • Ages 40-55
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Human Milk Oligosaccharides (HMOs) are the third most abundant class of nutrients in human milk. Studies investigating the effects of dietary HMOs in infants have shown various health and developmental benefits such as the development of the early gut microbiome (by favouring colonisation of beneficial Bifidobacterium, Lactobacillus, and Bacteroides), the development of the immune system, general infant growth, protection against infectious diseases and allergies, and stimulation of cognitive development. Only a limited number of studies have been conducted in adults, showing intake of HMOs stimulates the growth of gut Bifidobacterium in healthy adults.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 40 and ≤ 55 years

  • Male/female

  • Total score of >2 on the Gastrointestinal Symptom Rating Scale (GSRS)

  • Body Mass Index 18-30 kg/m2

  • Stable body weight (± 5%) for at least 6 months

  • Stable lifestyle and dietary habits within the 4 weeks prior and during study period

  • Owns device (computer, smartphone, tablet) with access to the internet

  • Adequate fluency in the English language to understand the inform consent process,study instructions and study assessments

  • Sufficient vision and hearing to complete study procedures

  • Willing and able to participate, follow the study procedures and to give writteninformed consent

Exclusion

Exclusion Criteria:

  • History (< 6 months prior to the study) or presence of severe gastrointestinal,metabolic, immunological, psychiatric disorder, or major surgery

  • Current or past (< 4 weeks) use of prescription, over-the-counter, or traditionalmedication, or dietary supplements with a relevant impact on GI system or onvisceral motility

  • Having received antibiotic treatment < 4 weeks prior to study

  • Alcohol intake >1 units/day

  • Currently pregnant or pregnancy in past 6 months

  • Use of pro/prebiotics < 4 weeks prior to study start

  • Fully vegetarian/vegan diet < 4 weeks prior to study start

  • High habitual vegetable and fruit intake (> 2 servings of fruits and >2 servings ofvegetables per day) < 4 weeks prior to study start

  • Lactose intolerance

  • Maltodextrin allergy

  • Members of the research team or their immediate family members. Immediate familymember is defined as spouse, parent, child, or sibling, whether biological orlegally adopted

Study Design

Total Participants: 108
Treatment Group(s): 3
Primary Treatment: Placebo
Phase:
Study Start date:
October 04, 2023
Estimated Completion Date:
September 30, 2025

Study Description

The current study aims to investigate the effects of a 4-week intervention with two HMOs on gut microbiome composition, immune function and gastrointestinal symptoms in healthy adults with mild to moderate gastrointestinal complaints. The study will be conducted as a partially decentralized, double-blind, randomized, placebo-controlled, parallel group design.

Connect with a study center

  • Singapore Institute for Clinical Trials

    Singapore, 117609
    Singapore

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.